You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信銘生命科技(00474.HK)就治療痛楚藥物許可簽署諒解備忘錄
格隆匯 03-24 18:59

格隆匯 3 月 24日丨信銘生命科技(00474.HK)發佈公吿,公司已與Scilex Holding(一間特拉華州公司)簽署諒解備忘錄,以就以下事項進行為期九十日的獨家磋商:

(a)Scilex SP-102(SEMDEXA)(“SP-102”)在大中華地區的獨家許可。SP-102是Scilex的專利藥品,在美國處於關鍵三期試驗,並獲美國食品及藥品監督管理局頒發快速審評資格;及(b)就公司向中國國家藥品監督管理局申請在中國內地進口、製造及銷售SEMDEXA或SP-102方面提供所須的臨牀前研究及臨牀測試數據。

諒解備忘錄概述Scilex與公司之間就SP-102(一種新型非鴉片類注射式黏性藥物,在大中華地區用於治療痛症及坐骨神經痛)的產品開發、製造及商業化權利的專營權。根據內部評估,大中華地區的獨家許可的預計總值將介乎6000萬美元至8000萬美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account